Allergic Rhinitis Clinical Trial
Official title:
Titrated Quantitative Conjunctival Provocation Test (tqCPT): Standardization and Validation of a New Clinical Endpoint
The clinical relevance of an allergen-specific sensitization is proven e.g., by allergen
challenge tests in clinical routine. Several protocols for different challenge tests such as
nasal (NPT), bronchial (BPT) or conjunctival provocation test (CPT) have been proposed.
Beneath others, the CPT is broadly used in both clinical trials and routine because of its
feasibility.
However, there is no internationally harmonized standard regarding the clinical
interpretation of CPT results as well as a lack of validation of a specific outcome score.
Therefore, this trial aims to investigate and validate a new scoring system for CPT results
in order to provide this test as a useful method in future clinical trials.
Of 33 patients who had been initially screened, ten patients did not fulfill all of the
inclusion criteria mentioned hereafter. Thus, 23 patients aged 18 to 67 years having a birch
and/or grass pollen allergy were included in the analysis. The study is in line with the
Declaration of Helsinki and is approved by the responsible ethics committee (FF 118/2012 (4
December 2012); Landesärztekammer Hessen, Frankfurt, Germany). All participating patients
are informed of the nature and objectives of the study and signed an informed consent
document.
The CPT is conducted using standardized and registered allergen extracts (ALK- Abelló,
Hørsholm, Denmark). At the first visit, a titrated quantitative CPT (tqCPT) is performed
according to a standardized protocol. In case of a positive test result, CPT-results are to
be confirmed at a re-challenge one week later. The final CPT takes place 3 to 4 weeks after
the 2nd (confirmatory) challenge for analyzing the primary objective of the trial:
reproducibility of the CPT symptom score. Furthermore, objective evaluation of the clinical
reactions after the tqCPT is documented using a MATLAB software program to calculate the
degree of redness in percent. This is then correlated with the (subjective) main
investigators' evaluations and with the external observer's evaluations.
;
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05080322 -
Efficacy and Safety of On-demand and Continuous Administration of Nasal Spray in the Treatment of Allergic Rhinitis
|
Phase 4 | |
| Recruiting |
NCT06028490 -
A Study of IL4Rα Monoclonal Antibody in Patients With Uncontrolled Seasonal Allergic Rhinitis.
|
Phase 2 | |
| Completed |
NCT04388358 -
Traditional Chinese Medicine for the Treatment of Perennial Allergic Rhinitis on Gut Microbiota and Immune-modulation
|
N/A | |
| Recruiting |
NCT04202263 -
Assessment of Suppression of Cutaneous Allergic Responses and Pruritis by Topical Minocycline
|
Phase 2 | |
| Completed |
NCT04078009 -
Standardising Nasal Allergen Challenge in Adult With Hay Fever
|
N/A | |
| Completed |
NCT03644680 -
Changes in Adaptive Immune Responses and Effector Cell Responses Upon Nasal Allergen Exposure - a Pilot Study
|
N/A | |
| Completed |
NCT04541004 -
Adolescent Mite Allergy Safety Evaluation
|
Phase 3 | |
| Recruiting |
NCT05378594 -
HDM and Silver Birch NAC Standardisation
|
N/A | |
| Not yet recruiting |
NCT05684380 -
Efficacy and Safety of MAZ-101 in the Treatment of Persistent Allergic Rhinitis (PER)
|
Phase 3 | |
| Not yet recruiting |
NCT01014325 -
Safety and Efficacy Study With Allergen Extracts of House Dust Mites for Specific Sublingual Immunotherapy
|
Phase 3 | |
| Completed |
NCT02943720 -
ATIBAR - Efficacy and Safety of Two Doses of AllerT in Patients Allergic to Birch Pollen
|
Phase 2 | |
| Completed |
NCT02910401 -
Clinical Response to Rhinovirus Challenge
|
Phase 2 | |
| Completed |
NCT02556801 -
Efficacy and Safety of SUBLIVAC Phleum for Immunotherapy of Grass Pollen-Allergy
|
Phase 2 | |
| Completed |
NCT02352168 -
Airway Inflammation in Children With Allergic Rhinitis and Intervention
|
N/A | |
| Not yet recruiting |
NCT02233426 -
Effect of Hypertonic Solutions on Allergic Rhinitis Patients
|
N/A | |
| Completed |
NCT01918956 -
PURETHAL Birch RUSH Study
|
Phase 4 | |
| Completed |
NCT01946035 -
Alpha-Blockers in Allergic Rhinitis (MAN 01)
|
Phase 4 | |
| Completed |
NCT01682070 -
SUBLIVAC FIX Phleum Pratense DT/DRF
|
Phase 2 | |
| Recruiting |
NCT01454492 -
The Relationship Between Allergic Rhinitis and Geographic Tongue
|
N/A | |
| Completed |
NCT01439815 -
An Allergen BioCube (ABC) Study Evaluating the Efficacy of Fluticasone Propionate Nasal Spray Compared to Placebo
|
Phase 4 |